None
Conditions
Interventions
Group One:Bioactive Low-Molecular-Weight Collagen Peptide Beverage (2.5g/day)
Group Three:Placebo Control Beverage (0g/day)
Group Two:Bioactive Low-Molecular-Weight Collagen Peptide Beverage (1g/day)
Sponsors
SGS – CSTC Standards Technical Services (Qingdao) CO., Ltd. Medical Test Lab.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Healthy females, aged 30–45 years; 2.Ethnicity: Asian (Chinese); 3.Baseline facial moisture content within the range of 15–50 a.u. ; 4.Baseline facial elasticity value (R2) <0.8; 5.Randomized selection of one side of the outer canthus with wrinkle severity graded at levels 3–7; 6.No significant facial skin lesions, scars, or hair; 7.No severe comorbidities of the heart, liver, or kidneys; 8.Willingness to abstain from using cosmetics, medications, or supplements that may affect study outcomes during the testing period; 9.No use of functional foods, skincare products, or anti-wrinkle, repair, or high-moisturizing products within one week prior to the study; 10.Understanding of the study process, voluntary participation, and written informed consent; 11.Ability to comply with the evaluation protocol, maintain regular lifestyle habits, and adhere to study requirements throughout the research period.
Exclusion criteria
Exclusion criteria: 1.Individuals unwilling to sign a photo consent form; 2.Those unwilling to comply with protocol requirements; 3.Individuals with a history of allergies or hypersensitivity to any component of the product; 4.Those with severe cardiac, hepatic, or renal impairment, or severe immunodeficiency; 5.Individuals with psychiatric disorders, severe endocrine diseases, or those taking oral contraceptives; 6.Individuals with alcohol or tobacco use disorders; 7.Those participating in any other clinical study concurrently; 8.Use of cosmetics or medications on the day of evaluation; 9.Pregnant, breastfeeding, or planning to conceive during the study period; 10.Individuals undergoing pharmacological treatment during the study period; 11.Those with dermatological conditions or atopic dermatitis that may affect study outcomes; 12.Presence of erythema, telangiectasia, or other skin abnormalities at the evaluation site; 13.Participation in any drug clinical trial or other study within the past month, or systemic use of medications affecting study results within the past week; 14.Individuals who underwent skin peeling or dermatological treatment within the past three months; 15.Those who received immunosuppressive therapy within the past three months; 16.Individuals who underwent systemic steroid therapy or phototherapy within the past month; 17.Use of specialized cosmetics (claiming anti-wrinkle, high-moisturizing, or repair effects) on the evaluation area within the past two weeks; 18.Lesions, visible scars, or other abnormalities in the evaluation area that interfere with measurements; 19.Individuals with severe reactions or allergies to cosmetics, medications, or general light exposure; 20.Any other condition deemed unsuitable for participation by the study investigator. 21.any medical beauty treatment in the two months prior to participating in the evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transdermal water loss rate;Tissue cell morphology (active epidermal thickness, DEJI, ELCOR, SAAID, cell density);Crow's feet (depth, length, area, volume);Skin moisture content;Skin elasticity and tightness;Skin thickness and density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Expert evaluation (skin firmness, skin glossiness, skin texture (visual smoothness), crow's feet);Subject self-assessment (provided by the customer);Consumer usage testing (provided by the customer); | — |
Countries
China
Contacts
Public ContactHe Wenjing
SGS –CSTC Standards Technical Services (Qingdao) Co.,Ltd.
Outcome results
None listed